Thanks to its expertise in clinical research, epidemiology, infectious diseases, microbiology, parasitology, public health, translational research and tropical medicine, coupled with deeply rooted partnerships with institutions in low- and middle-income countries (LMICs), the Swiss Tropical and Public Health Institute (Swiss TPH) has been a key contributor in many drug research and development consortia involving academia, pharma and product development partnerships. Our know-how of the maintenance of parasites and their life-cycles in the laboratory, plus our strong ties to research centres and disease control programme managers in LMICs with access to field sites and laboratories, have enabled systems for drug efficacy testing in vitro and in vivo, clinical research, and modelling to support the experimental approaches. Thus, Swiss TPH has made fundamental contributions towards the development of new drugs - and the better use of old drugs - for neglected tropical diseases and infectious diseases of poverty, such as Buruli ulcer, Chagas disease, food-borne trematodiasis (e.g. clonorchiasis, fascioliasis and opisthorchiasis), human African trypanosomiasis, leishmaniasis, malaria, schistosomiasis, soil-transmitted helminthiasis and tuberculosis. In this article, we show case the success stories of molecules to which Swiss TPH has made a substantial contribution regarding their use as anti-infective compounds with the ultimate aim to improve people's health and well-being.
Keywords: Drug research and development; Infectious diseases of poverty; Neglected tropical diseases; Product development partnerships; Swiss TPH.
Copyright 2023 Pascal Mäser, Sonja Bernhard, Reto Brun, Christian Burri, Sébastien Gagneux, Manuel W. Hetzel, Marcel Kaiser, Christian Lengeler, Gerd Pluschke, Elisabeth Reus, Matthias Rottmann, Jürg Utzinger, Louisa Warryn, Sergio Wittlin, Jennifer Keiser. License: This work is licensed under a Creative Commons Attribution 4.0 International License.